Q-omics provides the consensus-scored MTCO2P33 profile across patient tissues and cancer cell-line models. MTCO2P33 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, MTCO2P33 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, MTCO2P33 RNA expression shows 12,338 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, LUSC, and LSCC as cancer lineages where MTCO2P33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCO2P33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCO2P33 survival associations across molecular data types. MTCO2P33 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCO2P33 RNA expression–survival associations across cancer types. High MTCO2P33 expression shows unfavorable associations in COAD, LUSC, KIRC, THCA, HNSC and BRCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for MTCO2P33 RNA expression.
This table summarizes MTCO2P33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTCO2P33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCO2P33 shows lower tumor expression in LUSC. The LUSC box plot shows higher MTCO2P33 RNA expression in normal versus tumor tissue (log2 FC = −0.050, t-test p = .018).
This table shows molecular features associated with MTCO2P33 in patient tissues and cancer cell lines. In patient samples, MTCO2P33 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
